Cell-based immunotherapies for cancers and autoimmune disorders
Total Trials
1
As Lead Sponsor
As Collaborator
0
Total Enrollment
18
NCT02882659
Dendritic Killer Cell-based Immunotherapy for Solid Tumors
Phase: Phase 1
Role: Lead Sponsor
Start: Aug 31, 2014
Completion: Dec 31, 2017
Loading map...